This is a routine CFO appointment with no immediate financial impact. The key catalyst to watch is the upcoming NOVA-2 Phase 3 readout for LB-102 in schizophrenia, which the CEO referenced as the reason for this hire. Monitor for trial results and any associated financing or partnership announcements.
Price Chart
Executive Summary
LB Pharmaceuticals appointed Joseph M. Miller as CFO, effective September 2, 2026. Miller brings relevant experience from Aurinia Pharmaceuticals (commercial launch of LUPKYNIS) and other biotech firms. The filing is a routine executive appointment with no financial data or guidance changes, but the CEO's commentary highlights the upcoming pivotal NOVA-2 trial readout for LB-102, framing this hire as preparation for potential commercialization.
Key Facts
- Joseph M. Miller appointed CFO effective September 2, 2026.
- Miller previously served as CFO of Aurinia Pharmaceuticals (April 2020 to March 2026).
- Initial annual base salary of $530,000 with target bonus of 40% of base salary.
- Inducement option grant of 200,000 shares vesting over 4 years.
- CEO Heather Turner stated the company is approaching pivotal NOVA-2 clinical trial results for LB-102.
Financial Impact
No financial data or guidance provided in this filing.
Risk Factors
- No financial data or guidance was provided in this filing.
- The company's success depends on the outcome of the NOVA-2 clinical trial for LB-102.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-381076 |
| Document: d26110dex991.htm | 0001193125-26-381076 |
| Document: 0001193125-26-381076-index-headers.html | 0001193125-26-381076 |
| Document: 0001193125-26-381076-index.html | 0001193125-26-381076 |
| Document: 0001193125-26-381076.txt | 0001193125-26-381076 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 12d ago | SC 13G/A | $34.79 | awaiting T+60 | — | $39.42 (+13.29%) |
Oct 6, 2026 20d ago | EFFECT | $34.26 | awaiting T+60 | — | $39.42 (−15.05%) |
Sep 15, 2026 5w ago | 8-K | $43.04 | awaiting T+60 | — | $39.42 (−8.42%) |
Sep 3, 2026 7w ago | 8-K | $47.52 | awaiting T+60 | — | $39.42 (−17.06%) |
Aug 11, 2026 10w ago | 8-K | $45.33 | awaiting T+60 | — | $39.42 (−13.05%) |
Aug 11, 2026 10w ago | Press Release | $45.33 | awaiting T+60 | — | $39.42 (−13.05%) |
Jul 29, 2026 12w ago | 8-K | $39.00 $39.42 | ▲ +1.08% | ▼ −3.65% | $39.42 (+1.06%) |
Jul 22, 2026 13w ago | 8-K | $35.84 $36.69 | ▲ +2.37% | ▼ −0.89% | $39.42 (+9.97%) |
Jul 22, 2026 13w ago | Press Release | $35.84 $36.69 | ▲ +2.37% | ▼ −0.89% | $39.42 (+9.97%) |
Jun 10, 2026 19w ago | 8-K | $28.54 | awaiting T+60 | — | $39.42 (+38.10%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers